Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2011

01-04-2011 | Editorial

Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis?

Author: Fons AJ van de Loo

Published in: Arthritis Research & Therapy | Issue 2/2011

Login to get access

Abstract

It has long been recognized that laboratory tests are useful in the diagnosis of disease and to monitor treatment outcome. Their performance has become even more demanding with the development of personalized medicine. In patients with rheumatoid arthritis (RA) the standard biochemical tests measure serological markers of disease, such as C-reactive protein, and RA-associated auto-antibodies, such as rheumatoid factor and anti-citrullinated protein antibodies. The information obtained from these markers does not, however, provide a complete picture of the disease and treatment efficacy. New biomarkers based on cytokine receptor complexes are promising for RA theragnostics.
Literature
1.
go back to reference Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka S-I, Imaoka H, Kinoshita T, Honda S, Ida S, Fukuda T-A, Aizawa H: Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011, 13: R52-10.1186/ar3295.PubMedCentralCrossRefPubMed Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka S-I, Imaoka H, Kinoshita T, Honda S, Ida S, Fukuda T-A, Aizawa H: Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011, 13: R52-10.1186/ar3295.PubMedCentralCrossRefPubMed
2.
go back to reference Van Venrooij WJ, van Beers JJ, Pruijn GJ: Anti-CCP antibody, a marker for the early detection of RA. Ann N Y Acad Sci. 2008, 1143: 268-285. 10.1196/annals.1443.013.CrossRefPubMed Van Venrooij WJ, van Beers JJ, Pruijn GJ: Anti-CCP antibody, a marker for the early detection of RA. Ann N Y Acad Sci. 2008, 1143: 268-285. 10.1196/annals.1443.013.CrossRefPubMed
3.
go back to reference Van der Pouw Kraan TC, an Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: RA is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003, 48: 2132-2145. 10.1002/art.11096.CrossRefPubMed Van der Pouw Kraan TC, an Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: RA is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003, 48: 2132-2145. 10.1002/art.11096.CrossRefPubMed
4.
go back to reference Julià A, Erra A, an Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: An eight-gene blood expression profile predicts the response to infliximab in RA. PLoS One. 2009, 4: e7556-10.1371/journal.pone.0007556.PubMedCentralCrossRefPubMed Julià A, Erra A, an Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: An eight-gene blood expression profile predicts the response to infliximab in RA. PLoS One. 2009, 4: e7556-10.1371/journal.pone.0007556.PubMedCentralCrossRefPubMed
5.
go back to reference Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR: CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with RA. Clin Pharmacol Ther. 2010, 87: 311-321. 10.1038/clpt.2009.244.CrossRefPubMed Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR: CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with RA. Clin Pharmacol Ther. 2010, 87: 311-321. 10.1038/clpt.2009.244.CrossRefPubMed
7.
go back to reference Carrasco R, Barton A: Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports. 2010, 2: 26-38.CrossRef Carrasco R, Barton A: Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports. 2010, 2: 26-38.CrossRef
8.
go back to reference Dinarello CA: Interleukin-18 and the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2004, 30: 417-434. 10.1016/j.rdc.2004.02.001.CrossRefPubMed Dinarello CA: Interleukin-18 and the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2004, 30: 417-434. 10.1016/j.rdc.2004.02.001.CrossRefPubMed
9.
go back to reference Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van de Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest. 2001, 108: 1825-1832.PubMedCentralCrossRefPubMed Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van de Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest. 2001, 108: 1825-1832.PubMedCentralCrossRefPubMed
10.
go back to reference Veenbergen S, Smeets RL, Bennink MB, Arntz OJ, Joosten LA, van den Berg WB, van de Loo FA: The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis. 2010, 69: 276-283. 10.1136/ard.2008.100867.CrossRefPubMed Veenbergen S, Smeets RL, Bennink MB, Arntz OJ, Joosten LA, van den Berg WB, van de Loo FA: The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis. 2010, 69: 276-283. 10.1136/ard.2008.100867.CrossRefPubMed
11.
go back to reference Bresnihan B, Roux-lombard P, Murphy E, Kane D, FitzGerald O, Dayer J-M: Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis. 2002, 61: 726-729. 10.1136/ard.61.8.726.PubMedCentralCrossRefPubMed Bresnihan B, Roux-lombard P, Murphy E, Kane D, FitzGerald O, Dayer J-M: Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis. 2002, 61: 726-729. 10.1136/ard.61.8.726.PubMedCentralCrossRefPubMed
12.
go back to reference Rooney T, Murphy E, Benito M, Rou-Lombard P, FitxGerald O, Dayer J-M, Bresnihan B: Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004, 63: 1393-1398. 10.1136/ard.2003.016428.PubMedCentralCrossRefPubMed Rooney T, Murphy E, Benito M, Rou-Lombard P, FitxGerald O, Dayer J-M, Bresnihan B: Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004, 63: 1393-1398. 10.1136/ard.2003.016428.PubMedCentralCrossRefPubMed
13.
go back to reference Rooney T, Roux-Lombard O, Veale DJ, FitzGerald O, Dayer J-M, Bresnihan B: Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomized clinical trial of cytokine blockade. Ann Rheum Dis. 2010, 69: 706-714. 10.1136/ard.2009.108324.CrossRefPubMed Rooney T, Roux-Lombard O, Veale DJ, FitzGerald O, Dayer J-M, Bresnihan B: Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomized clinical trial of cytokine blockade. Ann Rheum Dis. 2010, 69: 706-714. 10.1136/ard.2009.108324.CrossRefPubMed
Metadata
Title
Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis?
Author
Fons AJ van de Loo
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3308

Other articles of this Issue 2/2011

Arthritis Research & Therapy 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.